A Phase 1b/2 Trial to Evaluate the Safety and Efficacy of Radium-223 Dichloride (BAY88-8223) in Combination With Bortezomib and Dexamethasone in Early Relapsed Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 25 Jul 2018
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Radium 223 chloride (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer
- 17 Jul 2018 Planned End Date changed from 24 Apr 2022 to 3 Jan 2022.
- 17 Jul 2018 Planned primary completion date changed from 24 Apr 2022 to 4 Dec 2021.
- 13 Oct 2017 Planned End Date changed from 22 May 2022 to 24 Apr 2022.